NIH PA-26-001: Administrative Supplements to Existing NIH Grants and Cooperative Agreements

NIH PA-26-001: Administrative Supplements to Existing NIH Grants and Cooperative Agreements

NIH PA-26-001 is a high-value mechanism for labs already holding a live NIH award who need additional funds to address legitimate, unforeseen cost pressures without starting a brand-new grant application. It is officially titled Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) and is designed for active projects where funding needs arise during execution.

This opportunity is especially relevant to 2026 and 2027 planning because it closes in late 2028 while supporting any eligible IC-specific application cycle, making it available for many 2026/27 submissions. It is not a new primary grant. It is a parent announcement for internal top-up funding routed through NIH’s administrative process.

Key details

1) What this opportunity is and why it matters in 2026/27

PA-26-001 is a mechanism for existing recipients rather than new applicants. It allows teams to request extra support when original budgets did not account for real-world changes. The parent announcement explicitly says these are requests for increased costs due to unforeseen circumstances and that funds are intended for activities that should fit the approved parent scope and timing.

For teams planning 2026/2027, this is often the only practical path when a project faces one of the following problems:

• New assay or sequencing costs that become necessary after project launch
• Staff capacity gaps due to delayed hiring or departures
• Unexpected animal model or sample procurement needs
• Additional pilot experiments needed to protect data quality and publication readiness
• Childcare or workforce-related supplemental expenses in training award contexts (documented as permitted)

Because it is tied to an active parent award and does not require a full review cycle, PA-26-001 can be faster and more flexible than starting a new application. But speed is not guaranteed; it is still constrained by IC-specific review and appropriations.

What it is not:

• Not a substitute for a peer-reviewed application to test a brand-new hypothesis
• Not a path for major changes in specific aims
• Not eligible when a request would alter the nature of the project in a way NIH classifies as scope change

2) Who should apply (or avoid)

Best fit

PA-26-001 is most suitable for PIs and institutions that already have:

• A currently active, in-compliance NIH grant or cooperative agreement
• A documented scientific need that clearly relates to that award
• Leadership and admin infrastructure able to submit through Grants.gov/ASSIST quickly
• Realistic scope alignment (the core requirement)

Who should avoid this route

Skip PA-26-001 if the team is asking for one of these:

• New scientific direction outside reviewed aims
• New disease focus not contemplated in the parent award
• Expansion into entirely new methods or populations that would require a new trial design approval at a different level
• Broad project expansion intended for longer-term institutional strategy rather than unforeseen costs

The rule-of-thumb that appears repeatedly in NIH language is: if it is not “within scope of the peer-reviewed and approved project,” PA-26-001 is often the wrong instrument.

Practical fit by role

• Principal Investigator: best positioned to justify why additional costs are indispensable and bounded by the existing design.
• Program official / AOR / grants staff: should validate whether the request is permissible under the parent award and institutional compliance environment.
• Institute/center contacts: useful for ambiguity about whether an IC accepts supplements in the intended use-case, especially with unusual components.

3) Eligibility, scope, and hard constraints

PA-26-001 is institutionally broad in organization type, but constrained operationally:

• The parent award must be active and not in a no-cost extension period
• Supplement activities must be completed within the competitive segment and within the competitive period constraints of the parent
• Supplemental work cannot extend beyond the term of the parent award
• Budgets and support periods are constrained by the parent award context
• Proposed work must remain within original peer-reviewed scope

The notice also carries a 2025-era NIH policy note affecting funded international collaborations with foreign subawards/subcontracts. In practice, teams should not use this NOFO for new foreign subawards; instead, they should use NOFOs explicitly designated for international collaboration. Foreign components, consultants, and procurement-related connections may still be possible under rules described by NIH.

The document identifies several eligible organization types (universities, nonprofits, government entities, small and for-profit organizations, tribal and regional entities, school districts, and others), but the controlling requirement remains “active NIH award + scope adherence + competitive segment feasibility.”

4) Dates, open status, and what “deadline” means here

The listing is posted with a global close date of 2028-11-30, but NIH supplements are not a single fixed-cycle grant in the same way many NSF submissions are. Due dates vary by awarding IC and call-in instructions.

For 2026 and 2027, interpret this as:

• The opportunity framework is open, not expired
• IC-level due dates and windows matter; they are not uniform
• Some ICs accept supplement submissions more often than others
• Teams should not assume a single “end-of-month one-shot” deadline

Because of this structure, the conservative planning approach is:

1. Confirm the IC-specific template and any special windows linked to the parent award IC.
2. Coordinate with your program office before finalizing submission date.
3. Aim for submission well before the IC due date to allow for corrections.

Also important: because the no-cost extension period is not eligible, PI/admin teams should time supplements before an award enters no-cost extension stage where possible.

5) Application workflow: step-by-step

Before submission

1. Verify award status
   • Confirm parent award is active and within competitive segment
   • Confirm no no-cost extension condition conflicts
2. Program discussion
   • Contact program officer and grants administrator early
   • Confirm request fits scope and is eligible at the IC level
3. Build a scope memo
   • Define the unforeseen event or need in 2–3 paragraphs
   • Link every requested item to existing peer-reviewed aims

Registration and access

NIH requires the institution to have active registrations in:

• System for Award Management (SAM)
• eRA Commons
• Grants.gov
• Any institution-specific routing required by your internal system

The full notice points to required forms and submission paths:

• NIH ASSIST, or
• Grants.gov Workspace, or
• Institutional system-to-system (S2S) submission

All paths require accurate completion of SF424 (R&R) forms and parent-award-linked details.

Critical form behavior

In the SF424 (R&R) package, the notice explicitly calls out behaviors that are easy to miss:

• Use “Revision” in Type of Application
• Match the descriptive title to the funded parent project
• Include the parent award EIN
• Provide supplemental-only budget and research plan sections (do not include unrelated costs)
• If human subjects or IACUC documentation is relevant, attach required materials
• Keep the research strategy focused on what the supplement adds to the active award

Submission hygiene

Before final submit:

• Open and validate the application in eRA Commons
• Check form-specific required fields for your selected package
• Ensure PD/PI credentials and organization identifiers are consistent across SAM/eRA/Grants.gov
• Submit early enough to fix technical errors

6) What reviewers and NIH staff evaluate

PA-26-001 requests are not peer reviewed. They are administratively evaluated by the NIH awarding component. That does not mean easier review; it usually means a tighter emphasis on compliance and scope.

Core evaluation themes

• Budget and project period reasonableness: does the amount requested directly support the unforeseen need?
• Overall impact within current award: does the supplement materially protect or improve outcomes without changing scope?
• Human subjects/animal sections: only as applicable, but these must still be complete and defensible
• Risk and biosecurity considerations: if relevant to the proposed activities
• Integrity and award history: NIH may review responsibility and qualification records

A frequent failure mode in this pathway is “scope drift,” where teams submit broad expansion requests and unintentionally trigger peer-review-level narrative without proper fit. The other repeated issue is incomplete administrative setup (wrong identifiers, wrong package, missing mandatory attachments), which can trigger delays or silent rejection.

7) Required materials and preparation checklist

Create a clean checklist for your team:

• Parent award identification numbers and activity code
• Current project abstract and funding segment evidence
• Budget justification tied to specific unforeseen need
• Revised work plan with limited scope and bounded period
• Staffing changes and effort breakdown for added personnel (if any)
• IACUC/IRB approvals where required by the change
• Signed internal approvals from grants office and PI

Additional NIH-specific reminders:

• The supplement request is a supplement to a specific funded project, not a standalone proposal
• Use the most conservative budget interpretation; NIH often reviews for reasonableness
• If you are requesting costs for a narrow workforce need (for example, childcare line-items in some training award contexts), follow specific instructions in the NOFO text

If your institution has multiple competing applications from the same PI, supplement requests do not count toward the six-application PI limit for most NIH internal rules in this pathway, but internal policies may still apply.

8) Strategy for 2026/2027 teams

For teams in active NIH cycles, the practical advantage is often timing. You can avoid waiting for a new parent submission if your need is truly additive and within current scope. But the opportunity is only useful if you treat it as an administrative instrument:

• Start with a “need statement tied to scope” memo
• Define exact cost categories and one-line justification per line
• Use internal pre-submission checks (administrative staff + science lead)
• Confirm no-cost extension implications
• Track submission windows per IC and target the earliest available slot

In 2026/2027 planning, a realistic workflow is to prepare a draft package as soon as the need is identified, then align it to the next IC cycle, rather than waiting for a full quarter-end cycle.

9) Common mistakes to avoid

1. Assuming NIH can fund major scope additions
   • PA-26-001 is not for stepping into new research territory.
2. Submitting with peer-review style breadth
   • Keep the request narrow and incremental.
3. Confusing funding instrument
   • It must follow the parent award mechanism and instructions.
4. Ignoring IC-specific due dates
   • The NOFO lists global dates, but the IC process is often segmented.
5. Missing registrations or stale identifiers
   • Missing SAM/eRA identity can trigger hard errors.
6. Using it for foreign subaward setups
   • Watch the international collaboration restrictions.

10) FAQs

Is this only for NIH institutes with open competition cycles?

No. It is for active NIH awards whose parent IC allows supplemental requests under this framework. IC timing differs, so verify with your program office.

Can my grant be in no-cost extension?

The notice states supplements are not permitted during no-cost extension in standard form, except rare emergency/disaster exceptions. Treat this as a hard planning constraint.

Are clinical-trial applications allowed?

The announcement is clinical-trial optional, but PI changes in trial designation are not permitted. Keep clinical design aligned to parent scope.

Are supplements peer reviewed?

No full peer review is described; NIH staff conduct administrative evaluation using criteria in the NOFO.

Can non-U.S. organizations apply?

Yes, in specific contexts and with restrictions. Non-domestic entities can be eligible in particular forms, but NIH has explicit restrictions on foreign subawards and monetary international collaborations under this NOFO.

Can I estimate available budget in advance?

No fixed award amount is published, and this depends on parent status, IC budgets, and appropriations. Expect this to be proposal-specific and contingent.

11) Official references

Use these official points of reference before you submit:

• PA-26-001 listing on Simpler.Grants.gov
• Revised full NOFO text
• NIH Grants & Funding parent site
• NIH administrative supplement guidance

Final readiness checklist

Before submitting a PA-26-001 request, verify that your team can answer yes to each item below:

• The parent award is active and within scope
• The request is for increased costs tied to unforeseen events
• The added work is explicitly bounded to the competitive period
• Registrations and eRA/SAM identifiers are current
• Form fields and attachments match the required package and package-specific required fields
• The IC has been contacted on interpretation questions
• A fallback submission plan exists if the first package encounters errors

If every item is confirmed, PA-26-001 can be a strong practical instrument for protecting ongoing NIH research momentum in 2026/2027 without waiting for a new award cycle.